

Message

From: Glenn, Barbara [Glenn.Barbara@epa.gov]
Sent: 11/12/2013 4:32:01 PM
To: Glenn, Barbara [Glenn.Barbara@epa.gov]; Bateson, Thomas [Bateson.Thomas@epa.gov]; Jinot, Jennifer [Jinot.Jennifer@epa.gov]; Subramaniam, Ravi [Subramaniam.Ravi@epa.gov]
CC: Kraft, Andrew [Kraft.Andrew@epa.gov]
Subject: RE: Issues/Trajectories Meeting - Thursday Nov. 14th
Attachments: IssuestrajectoriesCancerDecisions_111213.pptx

Hope you had a good long weekend. Here are the slides Andrew and I compiled to help us discuss the issues this Thursday. Could you look them over and let me know if we need to change anything. They are not polished but will suffice with this supposedly more informal setting. I'd like to send it this afternoon.

Thanks, Barbara

From: Glenn, Barbara
Sent: Friday, November 08, 2013 11:09 AM
To: Bateson, Thomas; Jinot, Jennifer; Subramaniam, Ravi
Cc: Kraft, Andrew
Subject: Issues/Trajectories Meeting - Thursday Nov. 14th

Hi Tom, Jennifer and Ravi,

I wanted to remind you about the issues/ trajectories meeting with John V, Lynn F et al next Thursday Nov. 14th at 9 am. We will be discussing numbers 3 (LHP Cancer Hazard) and 6 (our approach to dose-response for cancer IUR). We are hoping to limit the discussion on cancer dose-response to the decisions we made concerning our approach, and to put off discussions of the IUR values and how they compare with background death rates or incidence to the next meeting when we will talk about the RfCs and their relation to ambient levels of formaldehyde.

So we will be discussing the hazard decisions and our selection of RR for all leukemia instead of myeloid leukemia for the IUR selection of cumulative exposure, our interpretation of the "bottom up approach".

Ex. 5 Deliberative Process (DP)

Ex. 5 Deliberative Process (DP)

Andrew is compiling the graphs summarizing study results for myeloid leukemia, multiple myeloma, NPC and sinonasal cancer in a PP to attach to the calendar invite. We also will attach a table showing the RRs from the regression analyses for each of the exposure metrics examined by the NCI authors for NPC and LHP cancers.

We can set some time on Wednesday to talk about it or earlier in the week if you would like.

Thanks, Barbara and Andrew